Sodium Gualenate
CAS 6223-35-4
Sodium Gualenate (CAS 6223-35-4) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 16 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Hepatic function abnormal | 26 | 56.562 | 10019670 |
| Platelet count decreased | 33 | 46.71 | 10035528 |
| Interstitial lung disease | 23 | 37.337 | 10022611 |
| Pyrexia | 49 | 34.512 | 10037660 |
| White blood cell count decreased | 26 | 31.851 | 10047942 |
| Malignant neoplasm progression | 23 | 31.677 | 10051398 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sodium Gualenate used for in pharmaceutical contexts?
Sodium Gualenate (CAS 6223-35-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sodium Gualenate?
Sodium Gualenate has 16 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Hepatic function abnormal, Platelet count decreased, Interstitial lung disease, Pyrexia, White blood cell count decreased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sodium Gualenate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Guaiazulene Sulfonate with EU status "permitted".
What clinical phase is Sodium Gualenate in?
Sodium Gualenate is rendered with ChEMBL max phase 2.